Dover has entered into a definitive agreement to accumulate Malema Engineering Corp, a US designer and producer of high-precision, mission-critical flow-measurement and control devices for the biopharmaceutical, semiconductor and industrial sectors.
Malema’s merchandise will broaden Dover’s biopharma single-use manufacturing offering, which already includes Quattroflow pumps, CPC connectors, and em-tec flowmeters.
Based in Plain , Florida, and with amenities in San Jose, California, Singapore, South Korea and India, Malema expects to generate roughly US$40 million–45 million in revenue during the full 12 months 2022.
When the deal closes, Malema will become part of the PSG business unit inside Dover’s Pumps & Process Solutions segment.
“We see an incredible long-term progress opportunity in the bioprocessing trade driven by a powerful and rising pipeline of efficient novel biologic medication, biosimilars, protein therapies, non-COVID mRNA vaccines, in addition to budding cell & gene therapies,” says PSG’s president Karl Buscher. “Additionally, the rising adoption of more efficient single-use manufacturing processes supports a strong outlook for our choices of single-use components to end-customers. We consider that pairing Malema’s know-how with our current portfolio of single-use pumps for biopharma processing will greatly enhance the accuracy and worth proposition of our solutions to our customers.”
“We are methodically constructing out our biopharma platform via proactive capacity additions, new product improvement, and opportunistic acquisitions of highly-attractive area of interest part applied sciences,” said Richard Tobin, president and CEO of Dover. “Malema represents a strategic and highly-complementary flow-control and sensing expertise and further strengthens our sensor portfolio with new proprietary know-how. In addition to enticing biopharma functions, we count on sturdy progress within the semiconductor space on the capability expansion and re-shoring tailwinds.”
Share